Vonoprazan

47 interactions 4 explained in plain English

Also sold as: Voquezna

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Budesonide Mitapivat Olaparib Everolimus Budesonide Nasal Spray Axitinib

44 Major 3 Moderate

All (47) Major (44) Moderate (3)

Major

Vonoprazan Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Vonoprazan Clindamycin ANTIROBE Explained Increased CYP3A substrates exposure Details Vonoprazan Colchicine Colcrys Explained Increased CYP3A substrates exposure Details Vonoprazan Abemaciclib Verzenio Explained Increased CYP3A substrates exposure Details Vonoprazan Acalabrutinib Calquence Increased CYP3A substrates exposure Details Vonoprazan Axitinib Inlyta Increased CYP3A substrates exposure Details Vonoprazan Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Vonoprazan Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Vonoprazan Bedaquiline Sirturo Increased bedaquiline exposure Details Vonoprazan Bosutinib Bosulif Increased CYP3A substrates exposure Details Vonoprazan Brigatinib Alunbrig Increased CYP3A substrates exposure Details Vonoprazan Budesonide Entocort Increased budesonide exposure Details Vonoprazan Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Vonoprazan Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Vonoprazan Clindamycin Injection ANTIROBE Increased CYP3A substrates exposure Details Vonoprazan Clindamycin Topical C/T/S® Increased CYP3A substrates exposure Details Vonoprazan Clindamycin Vaginal Cleocin Increased CYP3A substrates exposure Details Vonoprazan Clopidogrel Plavix Reduced exposure of the active metabolite of clopidogrel Details Vonoprazan Cobimetinib Cotellic Increased CYP3A substrates exposure Details Vonoprazan Cyclosporine Injection Atopica Increased CYP3A substrates exposure Details Vonoprazan Cyclosporine Ophthalmic Cequa Increased CYP3A substrates exposure Details Vonoprazan Dasatinib Phyrago Reduced dasatinib absorption, reduced efficacy of dasatinib, increased dasatinib exposure and an increased risk of dasatinib-relat... Details Vonoprazan Digoxin Cardoxin® An increased risk of digoxin toxicity Details Vonoprazan Dihydroergotamine Injection DHE-45® Injection Increased CYP3A substrates exposure Details Vonoprazan Dihydroergotamine Nasal Spray Migranal Increased CYP3A substrates exposure Details Vonoprazan Docetaxel Beizray Increased DOCEtaxel exposure Details Vonoprazan Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Vonoprazan Dofetilide Tikosyn Increased CYP3A substrates exposure Details Vonoprazan Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Vonoprazan Entrectinib Rozlytrek Increased CYP3A substrates exposure Details Vonoprazan Everolimus Afinitor Increased everolimus exposure Details Vonoprazan Fentanyl Transdermal Patch Duragesic® Increased CYP3A substrates exposure Details Vonoprazan Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Vonoprazan Furosemide Injection Disal An increased risk of hypomagnesemia Details Vonoprazan Ketoconazole Topical Extina® Foam Reduced ketoconazole absorption, reduced efficacy of ketoconazole and an increased vonoprazan exposure Details Vonoprazan Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Vonoprazan Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Vonoprazan Methylergonovine Methergine Increased methylergonovine exposure Details Vonoprazan Midostaurin Rydapt Increased CYP3A substrates exposure Details Vonoprazan Mitapivat Aqvesme Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.